Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
BYOMass has appointed Dr. Declan Doogan and Dr. Stephen Hoffman to its Board of Directors. Dr. Doogan, a pharmaceutical veteran, previously led drug development at Pfizer and was Head of R&D at Amarin Corporation. Dr. Hoffman brings extensive experience from Aerpio Pharmaceuticals and has served on multiple biotech boards. Their expertise is expected to guide BYOMass’s innovative pipeline targeting the TGF-β superfamily, potentially improving therapies for diseases with high unmet medical needs.
Amarin Corporation plc (NASDAQ:AMRN) will host a conference call on November 3, 2021, at 7:30 a.m. ET to discuss its third quarter 2021 financial results. The call follows the anticipated release of financial results earlier that day. It can be accessed live via Amarin’s website or through designated phone numbers. A replay will be available for two weeks post-call. Amarin focuses on cardiovascular disease management and aims to enhance the treatment of cardiovascular risk.
Amarin Corporation plc (NASDAQ: AMRN) has announced a new Go-to-Market strategy to enhance the growth of VASCEPA® (icosapent ethyl) in the U.S. This includes improving healthcare professional engagement through an omnichannel platform, enhancing managed care access, and optimizing prescriptions for cardiovascular risk reduction. The strategy will reduce the U.S. sales force to approximately 300 representatives, reallocating resources towards educational efforts. Amarin aims to drive VASCEPA growth amidst increasing demand for cardiovascular therapies, emphasizing the drug's unique position as the only FDA-approved IPE product for CV risk reduction.
Amarin Corporation has successfully launched VAZKEPA (icosapent ethyl) in Germany, marking its first entry into the European market. VAZKEPA is designed to reduce cardiovascular risks in statin-treated adults with elevated triglycerides. The drug received approval from the European Commission in March 2021. Backed by over a decade of research, including the REDUCE-IT® study, VAZKEPA is endorsed by key cardiovascular disease treatment guidelines. The launch is a part of Amarin's growth strategy, aiming to address the significant cardiovascular burden in Europe, where CVD is the leading cause of death.
Amarin Corporation plc (NASDAQ: AMRN) announced participation in two upcoming virtual investment conferences in September 2021. The H. C. Wainwright 23rd Annual Global Investment Conference will feature an on-demand presentation available on September 13, 2021, at 7:00 a.m. ET. The Cantor Fitzgerald Global Healthcare Conference 2021 will include a live presentation on September 28, 2021, at 2:40 p.m. ET. Both presentations will be webcast live and archived for 90 days on Amarin's Investor Relations website.
Amarin Corporation (NASDAQ:AMRN) announced significant findings related to VASCEPA/VAZKEPA presented at ESC Congress 2021. The data revealed a 26% reduction in first and 35% reduction in total primary endpoints for patients with a history of myocardial infarction, reinforcing VASCEPA's role in cardiovascular risk reduction. Additionally, VAZKEPA was included in the 2021 ESC Guidelines for patients with elevated triglycerides, marking its 20th recognition in global guidelines. Despite promising findings, the identical PREPARE-IT 1 trial did not meet its primary endpoint.
Amarin Corporation (NASDAQ:AMRN) presented new analyses of VASCEPA® (icosapent ethyl) at ESC Congress 2021, revealing it reduces major adverse cardiovascular events in patients with prior myocardial infarction (MI) by 26% and total primary endpoints by 35%. Conducted as part of the REDUCE-IT study, these findings highlight VASCEPA's importance in cardiovascular risk management. Experts emphasize its efficacy in patients at high risk for recurrent events, further supporting its role as a treatment beyond statins.
Amarin Corporation has announced that new data supporting the efficacy of VASCEPA in preventing major adverse cardiovascular events will be presented at the ESC Congress 2021, taking place from August 27 to August 30, 2021. The presentations will include two Late-Breaking Science sessions and five e-Posters, showcasing research on icosapent ethyl. CEO Karim Mikhail highlighted the upcoming European launch of VASCEPA, starting in Germany, and anticipates results from the PREPARE-IT 1 trial, which investigates VASCEPA's role in COVID-19 prevention.
Amarin Corporation (NASDAQ:AMRN) reported a net revenue of $154.5 million for Q2 2021, marking a 14% increase from the previous year. The company is set to launch its cardiovascular drug VAZKEPA in Germany by September 2021, having filed market access dossiers in multiple European countries with a proposed pricing of approximately €200 per month. Amarin has received marketing authorization in Great Britain and aims for regulatory approval in 20 additional countries. The company ended Q2 with $523.1 million in cash and investments, enhancing its capacity for growth.
Amarin Corporation plc (NASDAQ:AMRN) announced a conference call to discuss its Q2 and H1 2021 financial results on August 5, 2021, at 7:30 a.m. ET. The call will be available on their investor relations website and via telephone. Investors are encouraged to follow the updates on their website for material information concerning Amarin's ongoing developments in cardiovascular disease management.